Sam Brusco, Associate Editor02.09.21
Vascular Perfusion Solutions Inc. (VPS) was granted a Breakthrough Device Designation from the FDA for its VP.S Encore oxygenated perfusion cardiac transport device.
The technology uses oxygen to help preserve vascularized tissue for eight hours. It also doubles the viability of organs beyond the current standard of care. As a self-contained device, VP.S Encore is portable (fits in the overhead compartment of a commercial airliner), affordable, and easy to use.
“We are thrilled that our VP.S Encore device has received a breakthrough device designation. VPS now has the priority to interact more quickly with the FDA, moving us closer to bringing VP.S Encore and its lifesaving technology to patients across the country, and eventually, the world,” Leonid Bunegin, VPS chief scientific officer said in a press release.
In the U.S. there are over 110,000 people on the national waiting list hoping to receive an organ transplant. Unfortunately, more than half of all donated organs are rejected because they can’t reach patients in time. Presently, organs available for transplant can remain viable for only four to six hours, severely limiting the travel distance to waiting recipients.
VPS received the designation in recognition of its effort to transform the world of organ preservation, resuscitation, and transport by removing the obstacles of time and distance with the creation of VP.S Encore.
VP.S Encore is initially focused on heart transport. It will later be extended to kidneys, livers, and lungs. It also will provide a platform for future uses like skin growth for burn victims.
The technology uses oxygen to help preserve vascularized tissue for eight hours. It also doubles the viability of organs beyond the current standard of care. As a self-contained device, VP.S Encore is portable (fits in the overhead compartment of a commercial airliner), affordable, and easy to use.
“We are thrilled that our VP.S Encore device has received a breakthrough device designation. VPS now has the priority to interact more quickly with the FDA, moving us closer to bringing VP.S Encore and its lifesaving technology to patients across the country, and eventually, the world,” Leonid Bunegin, VPS chief scientific officer said in a press release.
In the U.S. there are over 110,000 people on the national waiting list hoping to receive an organ transplant. Unfortunately, more than half of all donated organs are rejected because they can’t reach patients in time. Presently, organs available for transplant can remain viable for only four to six hours, severely limiting the travel distance to waiting recipients.
VPS received the designation in recognition of its effort to transform the world of organ preservation, resuscitation, and transport by removing the obstacles of time and distance with the creation of VP.S Encore.
VP.S Encore is initially focused on heart transport. It will later be extended to kidneys, livers, and lungs. It also will provide a platform for future uses like skin growth for burn victims.
